Fortress Biotech Licenses FB-607 for IBS-D, Drug in Phase 2 Trial

• Fortress Biotech’s majority-owned subsidiary entered an exclusive license agreement with Cedars-Sinai to develop FB-607 for irritable bowel syndrome with diarrhea.
• The rifaximin and N-acetylcysteine combination targets intestinal mucus and biofilms, potentially helping patients who do not fully respond to rifaximin alone.
• FB-607 is undergoing a randomized, placebo-controlled Phase 2 trial assessing safety, efficacy and pharmacokinetics in patients with the condition.
• The trial compares two dose levels with placebo over 14 days of treatment, with follow-up through week 14.
• Reported proof-of-concept results showed improvements in bowel symptoms, abdominal pain and bloating; the license also covers development for hepatic encephalopathy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortress Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611101605PRIMZONEFULLFEED9874707) on November 10, 2026, and is solely responsible for the information contained therein.